Skip to main content

Research Repository

Advanced Search

ABHISHEK ABHISHEK

Image

ABHISHEK ABHISHEK

Clinical Professor


Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation (2023)
Journal Article
Nakafero, G., Card, T., Grainge, M. J., Williams, H. C., Taal, M. W., Aithal, G. P., …Abhishek, A. (2023). Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation. eClinicalMedicine, 64, Article 102213. https://doi.org/10.1016/j.eclinm.2023.102213

Background: Patients established on thiopurines (e.g. azathioprine) are recommended to undergo three-monthly blood tests for the early detection of blood, liver, or kidney toxicity. These side-effects are uncommon during long-term treatment. We devel... Read More about Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation.

The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease (2023)
Journal Article
Abhishek, A., Tedeschi, S. K., Pascart, T., Latourte, A., Dalbeth, N., Neogi, T., …Choi, H. K. (in press). The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease. Arthritis and Rheumatology, https://doi.org/10.1002/art.42619

Objective Calcium pyrophosphate deposition (CPPD) disease is prevalent and has diverse presentations, but there are no validated classification criteria for this symptomatic arthritis. The American College of Rheumatology (ACR) and EULAR have develo... Read More about The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease.

Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK (2023)
Journal Article
Nakafero, G., Grainge, M. J., Williams, H. C., Card, T., Taal, M. W., Aithal, G. P., …Abhishek, A. (2023). Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK. BMJ, 381, Article e074678. https://doi.org/10.1136/bmj-2022-074678

OBJECTIVE: To develop and validate a prognostic model to inform risk stratified decisions on frequency of monitoring blood tests during long term methotrexate treatment. DESIGN: Retrospective cohort study. SETTING: Electronic health records within th... Read More about Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK.

The 2023 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Calcium Pyrophosphate Deposition (CPPD) Disease (2023)
Journal Article
Abhishek, A., Tedeschi, S. K., Pascart, T., Latourte, A., Dalbeth, N., Neogi, T., …Choi, H. K. (in press). The 2023 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Calcium Pyrophosphate Deposition (CPPD) Disease. Annals of the Rheumatic Diseases,

Dynamic assessment of the double contour sign by ultrasonography helps to distinguish between gout and calcium pyrophosphate deposition disease (2023)
Journal Article
Cipolletta, E., Abhishek, A., Di Matteo, A., Grassi, W., & Filippucci, E. (2023). Dynamic assessment of the double contour sign by ultrasonography helps to distinguish between gout and calcium pyrophosphate deposition disease. RMD Open, 9(1), Article e002940. https://doi.org/10.1136/rmdopen-2022-002940

Objective To test whether the double contour (DC) sign has a different dynamic behaviour in gout and calcium pyrophosphate deposition (CPPD) and whether the dynamic assessment of the DC sign increases its accuracy in gout diagnosis. Methods This cros... Read More about Dynamic assessment of the double contour sign by ultrasonography helps to distinguish between gout and calcium pyrophosphate deposition disease.

Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD (2023)
Journal Article
Card, T. R., Nakafero, G., Grainge, M. J., Mallen, C. D., Van-Tam, J. S. N., Williams, H. C., & Abhishek, A. (2023). Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD. American Journal of Gastroenterology, 118(8), 1388-1394. https://doi.org/10.14309/ajg.0000000000002205

INTRODUCTION: To investigate the association between vaccination against coronavirus disease 2019 (COVID-19) and inflammatory bowel disease (IBD) flare. METHODS: Patients with IBD vaccinated against COVID-19 who consulted for disease flare be... Read More about Is Vaccination Against COVID-19 Associated With Inflammatory Bowel Disease Flare? Self-Controlled Case Series Analysis Using the UK CPRD.

Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated (2023)
Journal Article
Atallah, E., Grove, J. I., Crooks, C., Burden-Teh, E., Abhishek, A., Moreea, S., …Aithal, G. P. (2023). Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated. Journal of Hepatology, 78(5), 989-997. https://doi.org/10.1016/j.jhep.2022.12.034

Background & Aims: The risk of significant liver fibrosis from prolonged methotrexate (MTX) exposure has been estimated at around 5%, prompting intensive monitoring strategies. However, the evidence is derived from retrospective studies that under-re... Read More about Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated.

Non-invasive markers of liver fibrosis for monitoring of long-term methotrexate therapy: A multi-centre longitudinal cohort study (2022)
Journal Article
Atallah, E., Grove, J., Crooks, C., Burden-Teh, E., Abhishek, A., Moreea, S., …Aithal, G. (in press). Non-invasive markers of liver fibrosis for monitoring of long-term methotrexate therapy: A multi-centre longitudinal cohort study. Journal of Hepatology,

Background: The risk of significant liver fibrosis from prolonged methotrexate (MTX) exposure has been estimated in around 5% of patients, which has led to intensive monitoring strategies. However, the evidence is derived from retrospective studies t... Read More about Non-invasive markers of liver fibrosis for monitoring of long-term methotrexate therapy: A multi-centre longitudinal cohort study.